SGLT2 inhibitors should be withheld or continue among patients undergoing cardiac coronary angiography SGLT2 inhibitor, AKI, Contrast-induced nephropathy, coronary angiography
Conditions
Interventions
Continuing SGLT2 inhibitors during coronary angiography,Withholding SGLT2 inhibitors 72 hours before coronary angiography
Experimental Other,Experimental Other
Continuing SGLT2 inhibitors,Withholding SGLT2 inhibitors
Sponsors
Central Chest Institute of Thailand
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age > 18 years old 2. Receive SGLT2 inhibitors at least 3 months prior the study 3. Elective coronary angiography
Exclusion criteria
Exclusion criteria: 1. Emergency catheterization included Primary PCI, Rescued PCI, pharmaco-invasive PCI in STEMI or STEMI within 7 days or unstable angina/NSTEMI within 72 hours 2.Patients with vasopressor or receive intra-aortic balloon pump (IABP) 3.Patients with stage 2-3 AKI or receiving RRT 4. Patients with DKA 5. Patients with NSAID or nephrotoxic agents use within 72 hours before coronary angiography 6.Patients who deny consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of Contrast induced nephropathy 48 hours Percent of CA-AKI | — |
Secondary
| Measure | Time frame |
|---|---|
| Cr 48 hours serum creatinine,RRT 48 hours Rate of RRT,Urine output 48 hours Urine output,Cardiac outcomes 48 hours Rate of AHDF, death, and MACE,Complication 48 hours Rate of DKA, urine ketone | — |
Countries
Thailand
Contacts
Public ContactPeerapat Thanapongsatornrn
Central Chest Institute of Thailand
Outcome results
None listed